These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29746267)

  • 1. Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis.
    Stellbrink HJ; Hoffmann C
    Curr Opin HIV AIDS; 2018 Jul; 13(4):334-340. PubMed ID: 29746267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
    Marzinke MA; Grinsztejn B; Fogel JM; Piwowar-Manning E; Li M; Weng L; McCauley M; Cummings V; Ahmed S; Haines CD; Bushman LR; Petropoulos C; Persaud D; Adeyeye A; Kofron R; Rinehart A; St Clair M; Rooney JF; Pryluka D; Coelho L; Gaur A; Middelkoop K; Phanuphak N; Cohen MS; Hendrix CW; Anderson P; Hanscom B; Donnell D; Landovitz RJ; Eshleman SH
    J Infect Dis; 2021 Nov; 224(9):1581-1592. PubMed ID: 33740057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1.
    McPherson TD; Sobieszczyk ME; Markowitz M
    Expert Opin Investig Drugs; 2018 Apr; 27(4):413-420. PubMed ID: 29633869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251.
    Andrews CD; Bernard LS; Poon AY; Mohri H; Gettie N; Spreen WR; Gettie A; Russell-Lodrigue K; Blanchard J; Hong Z; Ho DD; Markowitz M
    AIDS; 2017 Feb; 31(4):461-467. PubMed ID: 27902508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of cabotegravir for HIV treatment and prevention.
    Canetti D; Spagnuolo V
    Expert Opin Pharmacother; 2021 Mar; 22(4):403-414. PubMed ID: 33112699
    [No Abstract]   [Full Text] [Related]  

  • 6. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabotegravir long-acting for HIV-1 prevention.
    Andrews CD; Heneine W
    Curr Opin HIV AIDS; 2015 Jul; 10(4):258-63. PubMed ID: 26049951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
    Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
    Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
    Murray MI; Markowitz M; Frank I; Grant RM; Mayer KH; Hudson KJ; Stancil BS; Ford SL; Patel P; Rinehart AR; Spreen WR; Margolis DA
    HIV Clin Trials; 2018 Aug; 19(4):129-138. PubMed ID: 30445896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV.
    Bares SH; Scarsi KK
    Curr Opin HIV AIDS; 2022 Jan; 17(1):22-31. PubMed ID: 34871188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis.
    Pons-Faudoa FP; Sizovs A; Di Trani N; Paez-Mayorga J; Bruno G; Rhudy J; Manohar M; Gwenden K; Martini C; Chua CYX; Varchi G; Marzinke MA; Grattoni A
    J Control Release; 2019 Jul; 306():89-96. PubMed ID: 31136811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor.
    Kovač L; Časar Z
    Expert Opin Ther Pat; 2020 Mar; 30(3):195-208. PubMed ID: 31944142
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition.
    Fonner VA; Ridgeway K; van der Straten A; Lorenzetti L; Dinh N; Rodolph M; Schaefer R; Schmidt HA; Nguyen VTT; Radebe M; Peralta H; Baggaley R
    AIDS; 2023 May; 37(6):957-966. PubMed ID: 36723489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting injectable cabotegravir for the prevention of HIV infection.
    Clement ME; Kofron R; Landovitz RJ
    Curr Opin HIV AIDS; 2020 Jan; 15(1):19-26. PubMed ID: 31644481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The promise and pitfalls of long-acting injectable agents for HIV prevention.
    Landovitz RJ; Kofron R; McCauley M
    Curr Opin HIV AIDS; 2016 Jan; 11(1):122-8. PubMed ID: 26633643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabotegravir-Rilpivirine: The First Complete Long-Acting Injectable Regimen for the Treatment of HIV-1 Infection.
    Durham SH; Chahine EB
    Ann Pharmacother; 2021 Nov; 55(11):1397-1409. PubMed ID: 33593093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date.
    Whitfield T; Torkington A; van Halsema C
    HIV AIDS (Auckl); 2016; 8():157-164. PubMed ID: 27799824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation and pharmacology of long-acting cabotegravir.
    Trezza C; Ford SL; Spreen W; Pan R; Piscitelli S
    Curr Opin HIV AIDS; 2015 Jul; 10(4):239-45. PubMed ID: 26049948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection.
    Radzio-Basu J; Council O; Cong ME; Ruone S; Newton A; Wei X; Mitchell J; Ellis S; Petropoulos CJ; Huang W; Spreen W; Heneine W; García-Lerma JG
    Nat Commun; 2019 May; 10(1):2005. PubMed ID: 31043606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting antiviral agents for HIV treatment.
    Margolis DA; Boffito M
    Curr Opin HIV AIDS; 2015 Jul; 10(4):246-52. PubMed ID: 26049949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.